# Neurocrine Biosciences (NBIX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/NBIX
## Company Profile
- Ticker: NBIX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS, Endocrinology
## Stock Data
- Close: 159.82 USD
- Market cap: 15569159367.720001 USD
- Last updated: 2026-08-06
## Business Overview
### Neuroscience and Endocrinology Portfolio
Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline.
### Commercial Medicines
The portfolio includes FDA-approved treatments for tardive dyskinesia, Huntington’s disease chorea and classic congenital adrenal hyperplasia, as well as partnered medicines for endometriosis and uterine fibroids. INGREZZA and CRENESSITY provide the company’s principal wholly owned commercial franchises.
### Muscarinic Schizophrenia Programs
Neurocrine is developing multiple muscarinic receptor agonists for schizophrenia. NBI-1117570, a dual M1/M4 selective agonist, is in Phase 2 development, while direclidine is advancing through a Phase 3 program.
### Depression and Psychiatry Pipeline
Osavampator is in Phase 3 development for major depressive disorder. Together with the muscarinic programs, it broadens Neurocrine’s pipeline beyond movement disorders into large psychiatric indications.
### Emerging Obesity Program
NBIP-2118 is a corticotropin-releasing factor 2 receptor peptide agonist in first-in-human testing for obesity. The candidate also expands the company’s technical capabilities beyond traditional small molecules into peptide-based therapy.
### Rare-Disease Expansion
Neurocrine has agreed to acquire Soleno Therapeutics and its approved VYKAT XR therapy for hyperphagia in Prader-Willi syndrome. The transaction would strengthen the company’s presence in endocrinology and rare disease.
## Why The Stock Is Moving

The latest monitored company update is “Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Neurocrine’s watchlist is Ingrezza growth, the next CNS pipeline readout, and the company’s ability to keep the commercial base expanding. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.

## Recent News
- 2026-08-07 12:30 EST — [Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-590bdb3d) — Source: Neurocrine Biosciences
- 2026-07-30 20:01 EST — [Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2026-financial-results-6237f8ed) — Source: Neurocrine Biosciences
- 2026-07-23 20:05 EST — [Neurocrine Biosciences Announces Key Leadership Hiring, Promotions](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-key-leadership-hiring-promotions-40b9699b) — Source: Neurocrine Biosciences
- 2026-07-21 20:05 EST — [Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-appoints-samir-siddhanti-chief-business-officer-c85190fc) — Source: Neurocrine Biosciences
- 2026-07-09 20:01 EST — [Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-conference-call-and-webcast-of-second-quarter-2-bb26c15c) — Source: Neurocrine Biosciences